Hormone replacement therapy in postmenopausal women

被引:33
作者
Staren, ED [1 ]
Omer, S [1 ]
机构
[1] Med Coll Ohio, Dept Surg, Toledo, OH 43614 USA
关键词
cancer; coronary artery disease; estrogen; hormone replacement therapy; hot flashes; menopause;
D O I
10.1016/j.amjsurg.2003.12.063
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: For many years, hormone replacement therapy (HRT) was considered an effective method of restoring the relative protection from coronary artery disease enjoyed by premenopausal women compared with men of similar age. This view has been supported by a substantial number of basic science and observational studies. Data sources: Results of recent randomized controlled trials have seriously challenged the concept of the protective value of HRT by showing that rather than decreasing the risk of coronary artery disease, HRT actually appears to increase it. In addition, it increases the risk for breast cancer, stroke, venous thromboembolism, and cholecystitis. Results: Despite some benefits such as increased bone mineral density and decreased risk of fracture and colorectal cancer, these data suggest that the risks of HRT outweigh the benefits. Conclusions: HRT is no longer routinely recommended for prevention of chronic disease. We present the current scientific data, benefits, risks, and consequent clinical recommendations regarding HRT use in postmenopausal women. (C) 2004 Excerpta Medica, Inc. All rights reserved.
引用
收藏
页码:136 / 149
页数:14
相关论文
共 135 条
[1]   INHIBITION OF CORONARY-ARTERY ATHEROSCLEROSIS BY 17-BETA ESTRADIOL IN OVARIECTOMIZED MONKEYS - LACK OF AN EFFECT OF ADDED PROGESTERONE [J].
ADAMS, MR ;
KAPLAN, JR ;
MANUCK, SB ;
KORITNIK, DR ;
PARKS, JS ;
WOLFE, MS ;
CLARKSON, TB .
ARTERIOSCLEROSIS, 1990, 10 (06) :1051-1057
[2]   Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-up [J].
Alexander, KP ;
Newby, LK ;
Hellkamp, AS ;
Harrington, RA ;
Peterson, ED ;
Kopecky, S ;
Langer, A ;
O'Gara, P ;
O'Connor, CM ;
Daly, RN ;
Califf, RM ;
Khan, S ;
Fuster, V .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 38 (01) :1-7
[3]  
[Anonymous], 1974, NEW ENGL J MED, V290, P15
[4]  
[Anonymous], 2001, PRESCRIPTION DRUG TR
[5]   Raloxifene and cardiovascular events in osteoporotic postmenopausal women - Four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial [J].
Barrett-Connor, E ;
Grady, D ;
Sashegyi, A ;
Anderson, PW ;
Cox, DA ;
Hoszowski, K ;
Rautaharju, P ;
Harper, KD .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (07) :847-857
[6]   POSTMENOPAUSAL ESTROGEN AND PREVENTION BIAS [J].
BARRETTCONNOR, E .
ANNALS OF INTERNAL MEDICINE, 1991, 115 (06) :455-456
[7]  
Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0
[8]   Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures [J].
Black, DM ;
Cummings, SR ;
Karpf, DB ;
Cauley, JA ;
Thompson, DE ;
Nevitt, MC ;
Bauer, DC ;
Genant, HK ;
Haskell, WL ;
Marcus, R ;
Ott, SM ;
Torner, JC ;
Quandt, SA ;
Reiss, TF ;
Ensrud, KE .
LANCET, 1996, 348 (9041) :1535-1541
[9]   RISK-FACTORS FOR OVARIAN-CANCER - A CASE CONTROL STUDY [J].
BOOTH, M ;
BERAL, V ;
SMITH, P .
BRITISH JOURNAL OF CANCER, 1989, 60 (04) :592-598
[10]  
Breslau Erica S, 2003, J Am Med Womens Assoc (1972), V58, P33